by Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin’s lymphoma (NHL) with heterogeneous histopathological features and clinical behavior. It is the most common type of NHL worldwide, accounting for about 30% to 40% of newly diagnosed cases. The relapsed or refractory diffuse large B-cell lymphoma is harder to treat with traditional therapies. Novel therapies such as rituximab, brentuximab vedotin, and immune checkpoint inhibitors have expanded treatment options and improved patient outcomes. Rituximab in combination with chemotherapy has become the mainstay of treatment for DLBCL, increasing cure rates by 10-15% compared to chemotherapy alone.
The global Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The approvals of several novel drugs and treatment options have transformed the R/R DLBCL treatment landscape over the last few years. Brexucabtagene autoleucel (Tecartus) and Idecabtagene vicleucel (Abecma) are two CD19-directed chimeric antigen receptor (CAR) T-cell therapies approved in the United States for the treatment of adult patients with R/R DLBCL. In addition, Monjuvi (tafasitamab-cxix) a CD19-directed monoclonal antibody, received approval by the US FDA in June 2020. These approvals have provided more efficacious and targeted treatment options and driven the market growth. Furthermore, several pipeline drugs including Phase 3 assets such as Ubrogebutinib (Pharmacyclics), Ublituximab (TG Therapeutics), and Zanubrutinib (BeiGene) and Phase 2 assets like Alpelisib (Novartis) hold promise to further expand treatment options in the coming years.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderately high due to the need for extensive R&D capabilities and strong distribution networks in the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are many established companies offering treatment options for relapsed or refractory Diffuse Large B-cell Lymphoma.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of many suppliers and lack of product differentiation.
Threat of new substitutes: The threat of substitutes is moderate as researchers are constantly developing new treatment options.
Competitive rivalry: The competitive rivalry is high among key players to gain higher market share.
Key Takeaways
The Global Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Size is expected to witness high growth over the forecast period.
North America is expected to dominate the market owing to developed healthcare infrastructure and higher adoption of novel treatment options. The market in Asia Pacific is expected to witness fastest growth due to growing healthcare expenditure and increasing access to treatment.
Key players operating in the relapsed or refractory Diffuse Large B-cell Lymphoma market are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These companies are focusing on developing advanced treatment therapies through collaborations and acquisitions to strengthen their product portfolio and market position. For instance, in 2022 Hitachi partnered with a biotech company to develop a new targeted therapy drug for relapsed or refractory Diffuse Large B-cell Lymphoma patients.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
